Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Pharma Inc., a leading pharmaceutical company, is set to present new research findings at the European Society for Medical Oncology (ESMO) Congress 2023. The company aims to redefine expectations for patients with hard-to-treat cancers through its innovative oncology portfolio. With a total of 13 abstracts to be presented, Astellas will showcase data from two established medicines and one investigational therapy across prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers.

One of the highlights of Astellas’ presentations at the ESMO Congress is the Phase 3 EV-302 study of enfortumab vedotin in combination with pembrolizumab for previously untreated locally advanced or metastatic urothelial cancer. This late-breaking abstract demonstrates Astellas’ commitment to scientific advancements and addressing unmet needs in cancer care. The investigational therapy, developed in partnership with Seagen and in combination with Merck’s pembrolizumab, shows promising potential for improving outcomes in patients with urothelial cancer.

Additionally, Astellas will present expanded data from a Phase 3 study investigating enzalutamide plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence. This research highlights the company’s dedication to improving the quality of life for prostate cancer patients by exploring innovative treatment options.

Astellas has also made significant progress in its efforts to make a purposeful impact in the care of patients with advanced gastric cancer. The company will share updated data from two Phase 3 clinical studies evaluating zolbetuximab, an investigational therapy for gastric and GEJ cancer patients whose tumors are CLDN18.2-positive. These findings demonstrate Astellas’ commitment to providing effective treatment options for patients with limited treatment choices.

The collaborations between Astellas, Seagen, and Merck are crucial in advancing cancer research and treatment. The clinical collaboration agreement between Astellas and Seagen, along with Merck’s involvement, aims to evaluate the combination of PADCEV® (enfortumab vedotin-ejfv) and KEYTRUDA® (pembrolizumab) for previously untreated metastatic urothelial cancer. This collaboration showcases the commitment of these companies to developing innovative therapies and improving patient outcomes.

Furthermore, the collaboration between Pfizer and Astellas in the development and commercialization of XTANDI® (enzalutamide) demonstrates their joint efforts to address the needs of patients with nonmetastatic hormone-sensitive prostate cancer. This partnership allows for the global distribution and accessibility of XTANDI®, ensuring that patients worldwide can benefit from this innovative treatment option.

Astellas Pharma Inc. is a global pharmaceutical company operating in more than 70 countries. The company’s focus on the Focus Area Approach, which identifies opportunities for creating new drugs to address diseases with high unmet medical needs, showcases its commitment to advancing healthcare. Astellas is also exploring Rx+® healthcare solutions that combine its expertise with cutting-edge technology from external partners, further demonstrating its dedication to improving patient care.

As Astellas presents its latest research findings at the ESMO Congress 2023, it continues to be at the forefront of healthcare change, turning innovative science into value for patients. The company’s commitment to scientific advancements, strategic collaborations, and patient-centric approaches positions it as a leader in the field of oncology.

Leave a comment